AstraZeneca, Merck Say Lynparza Trial Shows Long-Term Survival Increase
September 09 2022 - 9:11AM
Dow Jones News
By Dean Seal
AstraZeneca PLC and Merck & Co. said Friday that long-term
follow-up results for trials of its Lynparza treatment showed
improved long-term survival for patients with advanced ovarian
cancer.
The companies, which jointly developed and commercialized the
medication, said a five-year follow-up of one trial showed 65.5%
survival in patients treated with Lynparza combined with
bevacizumab compared with 48.4% survival in a group given
bevacizumab and a placebo.
A seven-year follow-up of another trial showed 67% survival in
advanced ovarian cancer patients with BRCA mutations who received
Lynparza, compared with 47% in a placebo group.
Susan Galbraith, AstraZeneca's executive vice president of
oncology research and development, said the five-year survival rate
of newly diagnosed patients with advanced ovarian cancer is 30% to
50%.
"In that context, it is phenomenal to share the long-term
overall survival data from both PAOLA-1 and SOLO-1, with two out of
three patients still alive in these trials," she said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 09, 2022 08:56 ET (12:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
